# NCT06150157 (NCT06150157)

> A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06150157
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Neoplasms
- Interventions: JNJ-88549968; Ruxolitinib; Momelotinib
- Enrollment: 300
- Primary outcome: Part 1, Part 1b (US Only): Number of Participants With Dose Limiting Toxicity (DLT)
- Primary outcome: Part 1, 2, Part 1b (US Only), Part 2b (US Only): Number of Participants with Adverse Events (AEs)
- Primary outcome: Part 1, 2, Part 1b (US Only), Part 2b (US Only): Number of Participants with Adverse Events (AEs) by Severity

## Indexed commentary on NCT06150157 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 posts on X
- 1 post on Bluesky

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct06150157
